Recent Updates
Recently added Catalysts

Osteogenesis Imperfecta Type IV: one US-listed biotech with a clinical-stage programme

Rare Genetic & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.5Buniverse median $1.20B
Allocated capital$488M$1.5B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank200/299crowding rank 206

Osteogenesis Imperfecta Type IV is uncontested. Ultragenyx Pharmaceutical (RARE) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Setrusumab in phase 3.

There is no public comparable to price it against. RARE spreads its $1.5B market cap across 3 indications, so $488M of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$488M of allocated capital sits in Osteogenesis Imperfecta Type IV, ranking it 200th of 299 indications by the money committed to it.

Companies developing drugs for Osteogenesis Imperfecta Type IV 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
RAREUltragenyx PharmaceuticalSetrusumabPhase 34$1.5BNo3 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Osteogenesis Imperfecta Type IV counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Osteogenesis Imperfecta Type IV has one competitor and a median of $1.5B.

Rare Genetic & Metabolic

Rare Genetic & Metabolic holds $103B of the map's capital, 15.3% of the total, spread across 32 indications and 48 companies. 10 of those indications have more than one company competing.

See every Rare Genetic & Metabolic indication on the map

Related indications in Rare Genetic & Metabolic

Constipation Predominant Irritable Bowel Syndrome1 company · $462M · median $924MUncontestedParoxysmal Nocturnal Hemoglobinuria1 company · $461M · median $1.4BUncontestedGuillain-Barré Syndrome1 company · $459M · median $918MUncontestedErythropoietic Protoporphyria1 company · $609M · median $3.0BUncontestedEpidermolysis Bullosa Dystrophica1 company · $339M · median $339MUncontestedTransfusion Dependent Beta-thalassemia1 company · $330M · median $2.0BUncontestedPyruvate Kinase Deficiency1 company · $330M · median $2.0BUncontestedThalassemia1 company · $330M · median $2.0BUncontested

Osteogenesis Imperfecta Type IV pipeline questions

Which biotech companies are developing drugs for Osteogenesis Imperfecta Type IV?

Ultragenyx Pharmaceutical (RARE, Setrusumab, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Osteogenesis Imperfecta Type IV.

How advanced is the Osteogenesis Imperfecta Type IV pipeline?

Of the 1 clinical-stage programme in Osteogenesis Imperfecta Type IV, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Osteogenesis Imperfecta Type IV?

No. RARE is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Osteogenesis Imperfecta Type IV, which is why the indication is classified as uncontested.

When is the next Osteogenesis Imperfecta Type IV catalyst?

The next dated catalyst in Osteogenesis Imperfecta Type IV is RARE on 30 Sep 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map